一氧化氮与光化学法诱导大鼠脑缺血早期损伤的关系和绞股蓝总皂苷对脑缺血损伤的保护作用

目的：探讨一氧化氮(NO)与光化学法诱导大鼠脑缺血早期损伤的关系和绞股蓝总皂苷(Gyp)对脑缺血损伤的保护作用。方法：应用光化学法诱导大鼠大脑中动脉栓塞(MCAO)模型，观察氧合血红蛋白(OHb)和Gyp对MCAO后脑梗死范围，脑组织含水量、NO及超氧化歧化酶(SOD)、脂质过氧化产物TBARS含量的影响。结果：MCAO6h可导致大鼠局部脑组织明显梗死、脑水肿，同时SOD活力下降，TBARS含量升高，NO释放减少。OHb能进一步强化上述改变而Gyp能逆转上述变化。结论：脑内过氧化反应水平增高导致早期NO含量减少是脑缺血形成的重要原因之一，Gyp可通过影响脑缺血损伤早期脑内NO水平发挥对脑缺血的保护作用。     

低分子量肝素治疗进展型脑梗死及对血流变影响

目的:探讨低分子量肝素对进展型脑梗死的疗效及血流变影响.方法:将80例进展型脑梗死患者,随机分为治疗组40例,对照组40例.两组在治疗前后均行神经功能缺损评分和临床疗效评定,并观察其疗效及有关实验室指标,追踪随访1年.结果:治疗组的有效率明显高于对照组,不良反应轻微,PLT、APTT无明显变化,但血流变指标明显下降,1年内复发率明显小于对照组.结论:低分子肝素治疗进展型脑梗死疗效肯定,对于减少复发亦有一定作用,并可改善血流变.     

全视网膜光凝治疗糖尿病视网膜病变对视野影响的研究进展

糖尿病视网膜病变(DR)早期视野改变往往比视力更能及时反映病情进展。而全视网膜光凝(PRP)治疗DR在延缓病情进展的同时也造成了患眼视力下降和视野缩小等副作用。有研究表明,PRP治疗后的DR患者可因中心20°范围内的视野缺损而导致驾驶测试失败。为保证PRP疗效同时达到降低并发症的目的,激光技术不断改进与发展,通过调整激光参数、使用新型激光系统、与抗血管内皮生长因子(VEGF)药物联合、中西医结合治疗等方式可一定程度改善患眼视野,实现更佳疗效。未来可考虑在缺血指数(ISI)量化分析下,对视网膜缺血程度进行分级,依据ISI指标和视网膜无灌注区分布探索PRP治疗建议的最佳阈值及光凝范围,从而为DR患者提供更及时、更合理的个性化治疗方案。文章就PRP治疗DR对视野的影响进行简要综述。     

缬沙坦对颈动脉不稳定斑块患者血清炎症介质及缺血性脑卒中复发的影响

目的探讨缬沙坦对颈动脉不稳定斑块患者血清C-反应蛋白(CRP)、可溶性血管内皮细胞黏附分子-1(sVCAM-1)、白细胞介素-6(IL-6)的影响及对缺血性脑卒中复发干预的临床研究。方法不稳定斑块65例,缬沙坦治疗组33例,缬沙坦胶囊,80 mg,每日1次,口服,其他治疗措施与对照组基本相同。对照组32例,利尿降压药,口服。治疗前、1个月、2个月、38个月抽空腹静脉血共计5 ml,检测CRP、sVCAM-1、IL-6、血糖,同时监测血压。38个月时统计两组脑梗死复发和死亡情况,以CT或磁共振成像(MRI)出现新的梗塞灶为准。结果在1、2、38个月后治疗组血清CRP、sVCAM-1I、L-6浓度逐渐降低,组内相比差异有统计学意义(P<0.05),对照组除转变为硬斑者外其余变化不大。治疗组和对照组组间相比变化较大,差异有统计学意义(P<0.05)。终点38个月时,治疗组、对照组经CT或MRI证实脑梗死复发为7例(21.2%)和15例(46.9%)例,死亡为2例(6.1%)和5例(15.6%)例,治疗组复发率和病死率明显低于对照组(P<0.05)。结论缬沙坦稳定颈动脉斑块与血清中CRP、sVCAM-1I、L-6炎症介质的降低密切相关,降低不稳定斑块的破裂,从而减少了缺血性脑卒中的复发和死亡。     

Proteomic analysis of the effects of caffeine in a neonatal rat model of hypoxic‐ischemic white matter damage

AimWhite matter damage (WMD) is the main cause of cerebral palsy and cognitive impairment in premature infants. Although caffeine has been shown to possess neuroprotective effects in neonatal rats with hypoxic‐ischemic WMD, the mechanisms underlying these protective effects are unclear. Herein, proteins modulated by caffeine in neonatal rats with hypoxic‐ischemic WMD were evaluated.MethodsWe identified differential proteins and performed functional enrichment analyses between the Sham, hypoxic‐ischemic WMD (HI), and HI+caffeine‐treated WMD (Caffeine) groups. Confirmed the changes and effect of proteins in animal models and determined cognitive impairment via water maze experiments.ResultsIn paraventricular tissue, 47 differential proteins were identified between the Sham, HI, and Caffeine groups. Functional enrichment analyses showed that these proteins were related to myelination and axon formation. In particular, the myelin basic protein (MBP), proteolipid protein, myelin‐associated glycoprotein precursor, and sirtiun 2 (SIRT2) levels were reduced in the hypoxic‐ischemic WMD group, and this effect could be prevented by caffeine. Caffeine alleviated the hypoxic‐ischemic WMD‐induced cognitive impairment and improved MBP, synaptophysin, and postsynaptic density protein 95 protein levels after hypoxic‐ischemic WMD by preventing the HI‐induced downregulation of SIRT2; these effects were subsequently attenuated by the SIRT2 inhibitor AK‐7.ConclusionCaffeine may have clinical applications in the management of prophylactic hypoxic‐ischemic WMD; its effects may be mediated by proteins related to myelin development and synapse formation through SIRT2.     

清热化瘀Ⅱ号方对急性缺血性中风患者神经功能及中医证候评分的影响

目的通过观察清热化瘀Ⅱ号方对缺血性中风患者神经功能缺损评分、中医证候评分的影响,评价其对急性缺血性中风的中医证候疗效。方法选取急性缺血性中风患者72例,随机分为治疗组与对照组,每组36例。在常规治疗基础上,治疗组予清热化瘀Ⅱ号方治疗,对照组予天丹通络胶囊治疗,从K患者入院并筛选分组后开始给药,两组均治疗2周,观察并比较治疗前后两组患者神经功能缺损的评分、中医证候疗效及中医证候证候积分值。结果两组治疗前神经功能缺损评分差异无统计学意义（P〉0.05）,治疗后治疗组与对照组比较差异有统计学意义（P〈0.05或P〈0.01）。中医证候疗效总有效率治疗组为91.18%,对照组为71.43%,治疗组优于对照组（P〈0.05）,且治疗组中医证候积分减少明显优于对照组（P〈0.01）。结论清热化瘀Ⅱ号方可明显改善急性缺血性中风患者神经功能缺损评分及中医证候评分。     

Association between Geriatric Nutritional Risk Index and Depression after Ischemic Stroke

Background: Malnutrition is associated with poor outcomes after stroke. However, the association between malnutrition and post-stroke depression (PSD) remains unelucidated. We aimed to explore the association between geriatric nutritional risk index (GNRI) and depression after ischemic stroke. Methods: In total, 344 patients with ischemic stroke were included in this analysis. The GNRI was calculated from serum albumin level, weight, and height at admission. Malnutrition was defined using the GNRI cutoff points. A lower GNRI score indicates an elevated nutritional risk. The outcome was depression, measured 14 days after ischemic stroke. Logistic regression models were used to estimate the association between the GNRI and risk of PSD. Results: A total of 22.9% developed PSD 14 days after stroke. The mean GNRI was 99.3 ± 6.0, and 53.8% of the patients had malnutrition. After adjusting for covariates, baseline malnutrition was not associated with risk of PSD (OR, 0.670; 95%CI, 0.370–1.213; p = 0.186). The restricted cubic splines revealed a U-shaped association between the GNRI and PSD. Compared to moderate GNRI, higher GNRI (OR, 2.368; 95%CI, 0.983–5.701; p = 0.085) or lower GNRI (OR, 2.226; 95%CI, 0.890–5.563; p = 0.087) did not significantly increase the risk of PSD. Conclusion: A low GNRI was not associated with an increased risk of depression after ischemic stroke.     

Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021

BackgroundTo assess the temporal changes in the characteristics of ischemic stroke drug clinical trials conducted in mainland China in 2005–2021.MethodsA statistical analysis of registered clinical trials on ischemic stroke was performed using the platform of the Center for Drug Evaluation of China National Medical Products Administration, the Chinese Clinical Trial Registry, and ClinicalTrials.gov websites.ResultsFrom January 1, 2005 to August 1, 2021, a total of 384 registered drug clinical trials on ischemic stroke were identified in mainland China. Over time, the number of trials gradually increased each year, with a significant growth in 2014, from 16 in 2013 to 42 in 2014. Phase IV trials (31.8%) accounted for the majority, followed by phase II (16.4%), phase I (10.9%), and phase III (8.6%). In terms of sponsorship, the proportion of investigator‐initiated trials (IITs) (60.7%) was higher than industry‐sponsored trials (ISTs) (39.3%). Additionally, trials involving traditional Chinese medicines (TCMs) (36.2%) accounted for the largest proportion, followed by trials involving antithrombotic therapy (19.5%) and cerebral protection agents (16.7%). Furthermore, over the past 17 years, the number of leading drug clinical trial units for ischemic stroke in mainland China has continuously increased. The leading principal units from Beijing, Shanghai, Guangdong, Jiangsu, and Liaoning accounted for the majority of the trials (67.4%).ConclusionIn the past 17 years, great progress has been made in the research and development (R&D) of drugs and clinical trials for ischemic stroke in mainland China. The most extensive progress was observed in TCMs, antithrombotic therapy, and cerebral protection agents. More clinical trials are needed to confirm whether the newly developed drugs can improve the clinical efficacy of ischemic stroke. Simultaneously, more pharmaceutical R&D efforts of innovative drugs are warranted.     

骨髓干细胞移植治疗缺血性心脏病的研究进展

干细胞具有自我更新，多向分化能力，在适宜的体外培养中干细胞能够稳定生存增殖并保持多向分化潜能，是便于体外操作的理想的靶细胞。本综合近几年国内外献，阐述了骨髓干细胞通过移植技术移植至试验动物的病损心脏，可以分化增殖为心肌细胞和血管结构，从而改善缺血的心脏功能。因此具有广阔的临床应用前景，值得进一步研究。